- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Medicine
Volume 2013 (2013), Article ID 747431, 4 pages
Cerebral Venous Thrombosis Revealing Primary Sjögren Syndrome: Report of 2 Cases
1Department of Neurological and Psychiatric Sciences, Sapienza University of Rome, Viale dell'Università 30, 00185 Rome, Italy
2Department of Physical Medicine and Rehabilitation, Sapienza University of Rome, P.le Aldo Moro, 5, 00185 Rome, Italy
Received 11 October 2012; Revised 3 December 2012; Accepted 17 December 2012
Academic Editor: W. Zidek
Copyright © 2013 A. Mercurio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sjögren syndrome (SS) is an autoimmune disease of the exocrine glands, characterized by focal lymphocytic infiltration and destruction of these glands. Neurologic complications are quite common, mainly involving the peripheral nervous system (PNS). The most common central nervous system (CNS) manifestations are myelopathy and microcirculation vasculitis. However, specific diagnostic criteria for CNS SS are still lacking. We report two cases of primary SS in which the revealing symptom was cerebral venous thrombosis (CVT) in the absence of genetic or acquired thrombophilias.
The prevalence of neurological involvement in Sjögren’s syndrome (SS) ranges between 8% and 70% [1, 2]. The central nervous system (CNS) is involved in 1.5%–36% of SS patients, but its prevalence might be underestimated . Indeed, CNS manifestations in SS are various and may involve the entire neuroaxis. This variability of neurologic presentation may delay the diagnosis .
Headache is the main CNS complication in SS. In addition, subclinical tissue injury may be determined by magnetic resonance imaging (MRI). The diagnosis of systemic disease is still based on clinical features and laboratory findings but some characteristic MRI findings exist . Ferreiro et al. first reported a patient with diffuse angiographic changes, suggesting that CNS vasculitis may be the symptom of onset in some SS patients .
Antiphospholipid antibodies (aPL) are observed in 2%–37% of SS patients and may be responsible for thromboembolic events and fetal loss . Nevertheless, thrombosis may also occur in the absence of aPL. To date, only one case of cerebral venous thrombosis (CVT) as the symptom of onset of SS has been reported. It was associated with myeloradiculopathy .
Herein, we present two cases of isolated transverse sinus (TS) thrombosis as the revealing symptom of primary SS. The patients had no genetic or acquired thrombophilias.
2. Material and Methods
2.1. Case 1
A 43-year-old woman was admitted to our neurological ward because of severe headache associated with vomiting and generalized seizures. The pain was restricted to the left temporal area and irradiating to the neck. Her past clinical history was unremarkable except for oral and ocular sicca syndrome and recurrent cavities.
Brain MRI revealed a left parietal hematoma, while the MR venography (MRV) showed an ipsilateral TS thrombosis (Figure 1). She was treated with IV heparin followed by oral anticoagulant.
The patient underwent an extensive screening for coagulation disorder, included in the screening for thrombophilias, as we normally perform in any patient with CVT . It includes protein C deficiency, protein S deficiency, antithrombin deficiency, activated protein C resistance, Leiden mutation of factor V gene, G20210A prothrombin mutation, homocysteine, and MTFHR mutations. The patient was also screened for the presence of autoantibodies: aPL, ANA, ENA, ANCA, and AMA. The aPL tested IgG and IgM anticardiolipin antibodies (aCL), IgG and IgM anti-β2 glycoprotein-1 antibodies (aβ2GPI), and lupus anticoagulant (LA) according to the guidelines of the International Society on Thrombosis and Haemostasis .
The patient showed positive ANA (+++), ENA, and anti-Ro/SS-A antibodies. aPLA (repeated in other two occasions at least 12 weeks apart) were negative. Since the parotid scintigraphy, the biopsy of minor salivary glands, Schirmer test, and BUT were positive, the European criteria of Vitali for SS were satisfied (Table 1) . She was treated with hydroxychloroquine and at the 3-year followup she had no clinical or radiological relapse and fully recovered. No delayed recanalization was observed at the MRV.
2.2. Case 2
A 44-year-old woman admitted to our ward for the sudden onset of intracranial hypertension syndrome associated with right hemiparesis and ipsilateral seizures followed by secondary generalization. The patient had a clinical history of recurrent otitis, mucosal dryness, and recurrent hands’ arthralgias. The brain MRI showed a left temporal hematoma while the MRV revealed a left TS thrombosis (Figures 2(a) and 2(b)). She was treated with LMWH followed by oral anticoagulant.
The same screening for coagulation disorder described previously was applied, and the patient showed positivity to ANA (+++), pANCA, antiRo/SS-A, and antiLa/SS-B antibodies. Also RA test was positive. aPL were negative. The diagnostic workup allowed the diagnosis of primary SS (Table 1). Hydroxychloroquine was introduced and at the 5-year followup she had no clinical or radiological relapse and fully recovered. Again, at the MRV no delayed recanalization was observed.
SS is an autoimmune disorder, more prevalent in young women (0.5%–1% of the general population with a F/M ratio = 9 : 1), HLA DR3-related and characterized by a lymphocyitic aggression of the exocrine glands . Extraglandular manifestations are common. CNS involvement may be represented by myelitis, vasculitis of the microcirculation, associated with white matter lesions, aseptic meningitis, and encephalopathy [2, 11]. Arterial stroke has also been reported [2, 4, 12].
In the sole other case of CVT in SS patient previously described , the revealing symptom of SS was a myelitis, followed by TS thrombosis. Also in that case, no thrombophilic factors were detected.
According to Hughes and Khamashta there might be 3 different possibilities to explain thromboembolic events occurring in seronegative patients: (1) a seronegative phase of a previously positive aPL; (2) conventional laboratory testing failing to pick up cases with antibodies directed against different phospholipids or proteins cofactors; (3) the presence of a different coagulopathy . The diagnosis of seronegative aPL has been suggested for patients with clinical manifestations indicative of aPL but with persistently negative results in the commonly used assays to detect aCL antibodies, aβ2GPI, and LA. To date the best management of these patients is still unclear . It is possible that currently available assays cannot detect all potential aPL. Moreover, new specificities are tested in only a few research laboratories. Some patients that are “seronegative” for aPL may occasionally have antibodies against other membrane phospholipids such as phosphatidylserine, phosphatidic acid and phosphatidylinositol, that are not determined in routine blood test . In this respect, phosphatidylethanolamine antibodies (aPE) are detected in stroke patients with suspected aPL in the absence of LA or aCL antibodies .
We cannot exclude that CVT in our patients might be due to other aPL factors, such as aPE. Unfortunately, these antibodies are not routinely assessed in our laboratory. On the other hand, our report suggests that, in patients with CVT, primary SS should be suspected, even in the absence of thrombophilic risk factors.
In a large series of Italian SS patients, 5.8% of them had CNS involvement. None of them presented with CVT. However, 50% presented with “subacute encephalopathy” characterized by memory loss, cognitive dysfunction, and visual disturbances . Whether some of these cases might be due to unrecognized CVT remains undetermined.
In conclusion, CNS impairment in SS is probably more heterogeneous than commonly believed. A well-defined management protocol awaits studies with larger case numbers  while specific criteria and guidelines for primary CNS SS are still lacking.
In patients with CVT primary SS should be suspected, even in the absence of thrombophilic risk factors. Since conventional laboratory testing may fail to detect uncommon coagulopathies, it might be wise to repeat the screening tests in more than one occasion. When possible, patients should be screened for other and more rare aPL.
- R. I. Fox, “Sjögren’s sindrome,” The Lancet, vol. 366, pp. 321–331, 2005.
- C. Lafitte, Z. Amoura, P. Cacoub et al., “Neurological complications of primary Sjögren's syndrome,” Journal of Neurology, vol. 248, no. 7, pp. 577–584, 2001.
- L. Michel, F. Toulgoat, H. Desal et al., “Atypical neurologic complications in patients with primary Sjögren's syndrome: report of 4 cases,” Seminars in Arthritis and Rheumatism, vol. 40, no. 4, pp. 338–342, 2011.
- A. Massara, S. Bonazza, G. Castellino et al., “Central nervous system involvement in Sjögren's syndrome: unusual, but not unremarkable-clinical, serological characteristics and outcomes in a large cohort of Italian patients,” Rheumatology, vol. 49, no. 8, pp. 1540–1549, 2010.
- J. E. Ferreiro, B. D. Robalino, and M. J. Saldana, “Primary Sjogren's syndrome with diffuse cerebral vasculitis and lymphocytic interstitial pneumonitis,” American Journal of Medicine, vol. 82, no. 6, pp. 1227–1232, 1987.
- A. L. Fauchais, M. Lambert, D. Launay et al., “Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients,” Lupus, vol. 13, no. 4, pp. 245–248, 2004.
- E. Urban, B. Jabbari, and H. Robles, “Concurrent cerebral venous sinus thrombosis and myeloradiculopathy in Sjogren's syndrome,” Neurology, vol. 44, no. 3 I, pp. 554–556, 1994.
- M. Altieri, A. Mercurio, V. Di Piero, E. Vicenzini, and G. L. Lenzi, “Complete versus partial lateral sinus thrombosis: a pathophysiological hypothesis,” European Neurology, vol. 59, no. 3-4, pp. 127–130, 2008.
- R. Cervera, F. Conti, A. Doria, L. Iaccarino, and G. Valesini, “Does seronegative antiphospholipid syndrome really exist?” Autoimmunity Reviews, vol. 11, pp. 581–584, 2012.
- C. Vitali, S. Bombardieri, R. Jonsson, et al., “Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group,” Annals of the Rheumatic Diseases, vol. 61, pp. 554–558, 2002.
- T. Gono, Y. Kawaguchi, Y. Katsumata et al., “Clinical manifestations of neurological involvement in primary Sjögren's syndrome,” Clinical Rheumatology, vol. 30, no. 4, pp. 485–490, 2011.
- M. Bragoni, V. Di Piero, R. Priori, G. Valesini, and G. L. Lenzi, “Sjogren's syndrome presenting as ischemic stroke,” Stroke, vol. 25, no. 11, pp. 2276–2279, 1994.
- G. R. V. Hughes and M. A. Khamashta, “Seronegative antiphospholipid syndrome,” Annals of the Rheumatic Diseases, vol. 62, no. 12, p. 1127, 2003.
- H. Meijide, S. Sciascia, G. Sanna, M. A. Khamashta, and M. L. Bertolaccini, “The clinical relevance of IgA anticardiolipin and IgA anti-2 glycoprotein I antiphospholipid antibodies: a systematic review,” Autoimmunity Reviews. In press.
- H. L. Staub, M. L. Bertolaccini, and M. A. Khamashta :, “Anti-phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome,” Autoimmunity Reviews, vol. 12, no. 2, pp. 230–233, 2012.
- A. Massara, S. Bonazza, G. Castellino et al., “Central nervous system involvement in Sjögren's syndrome: Unusual, but not unremarkable-clinical, serological characteristics and outcomes in a large cohort of Italian patients,” Rheumatology, vol. 49, no. 8, pp. 1540–1549, 2010.